AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal TrialBenzinga • 11/10/25
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trialBusiness Wire • 11/09/25
Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of diseaseBusiness Wire • 11/07/25
AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs OutperformZacks Investment Research • 11/06/25
Compared to Estimates, Astrazeneca (AZN) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/06/25
AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales SoarInvestors Business Daily • 11/06/25
BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025Accesswire • 11/03/25
AstraZeneca to face questions on Trump MFN deal, patent expiries and pipelineProactive Investors • 10/31/25
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 10/28/25
AstraZeneca found in breach of industry code over Symbicort marketing, industry body saysReuters • 10/24/25